ERAS-0015

Small molecule

Also known as JYP0015

Earlyevidence

Evidence outlook

Non-Small Cell Lung Cancer: mid-stage studies underway, no completed readout

In Non-Small Cell Lung Cancer, Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. Studies in other indications have read out; see the trials and Regulatory events below.

Also in development:Pancreatic Ductal Adenocarcinoma · Phase 2

Featured evidence outside this drug's tracked markets:AURORAS-1 (NCT06983743) · Metastatic Solid Tumors · Phase 1 · ungraded

Company guidance: topline data expected later this year (Erasca, 11 Aug 2026). “Our recent financing should position us to accelerate ERAS-0015 toward three potentially registration-enabling trials while maintaining momentum across our broader pipeline, including the upcoming ERAS-4001 clinical data readout expected later this year.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Pancreatic Ductal Adenocarcinoma
Phase 1/2 (1)
Pancreatic Ductal Adenocarcinoma
NCT07897734 · Tango Therapeutics, Inc.
2026-11 – 2032-05 · PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic, Thoracic Cancer
What this study did
Phase 1 (1)
Other / comorbidity
NCT06983743 · Erasca, Inc.
2025-06-05 – 2028-12-01 · Metastatic Solid Tumors
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for Pancreatic Ductal Adenocarcinoma: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
ERAS-0015: this drugPhase 2Small moleculepan-RASnot yet gradedNo reviewed efficacy summary in this indication
Daraxonrasib (Rasonque)ApprovedSmall moleculepan-RAS, RAS (pan-RAS, RAS-mutant tumors)Partial signalNo reviewed efficacy summary in this indication
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)not yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
INCB161734Phase 3Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
QuemliclustatPhase 3Small moleculeCD73 (NT5E)not yet gradedNo reviewed efficacy summary in this indication
SetidegrasibPhase 3Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
NavlimetostatPhase 2/3Small moleculePRMT5 (protein arginine methyltransferase 5), MTA-cooperative bindingnot yet gradedNo reviewed efficacy summary in this indication
Autogene CevumeranPhase 2Vaccine—not yet gradedNo reviewed efficacy summary in this indication
GFH375Phase 2Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
Nuzefatide PevedotinPhase 2PeptideEphA2not yet gradedNo reviewed efficacy summary in this indication
ARV-806
Phase 1/2(overall)
Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
VopimetostatPhase 1/2Small moleculePRMT5not yet gradedNo reviewed efficacy summary in this indication
HSK41959
Phase 1(overall)
Small moleculePRMT5not yet gradedNo reviewed efficacy summary in this indication
LY4066434
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
PF-07934040
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow ERAS-0015 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
May 2028 (1)
Phase 1Metastatic Solid TumorsRecruiting
Est. primary completion 2028-05-01 · NCT06983743 · CT.gov ↗
What to watch
2031 (1)
November 2031 (1)
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-11 · NCT07897734 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

January 2026Topline resultErasca reports first responses with ERAS-0015 in AURORAS-1
US · Erasca · Source ↗